PLAZOMICIN

Plazomicin is a next-generation aminoglycoside antibiotic developed for the treatment of serious bacterial infections. It is specifically designed to combat multidrug-resistant (MDR) pathogens, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin works by inhibiting bacterial protein synthesis, leading to cell death.

Indications

-Complicated urinary tract infections (cUTIs), including pyelonephritis caused by MDR pathogens. -Infections caused by carbapenem-resistant Enterobacteriaceae (CRE) in certain cases. -Use is reserved for situations where alternative treatments are not suitable.

Dosage

-Standard dosage: 15 mg/kg administered as an intravenous infusion over 30 minutes once daily. -Duration: Typically 4 to 7 days or as prescribed based on infection severity and clinical response.

Contra-Indications

-Hypersensitivity to plazomicin or other aminoglycosides. -Severe renal impairment without appropriate monitoring.

Special Precautions

-Nephrotoxicity: Risk increases with prolonged use or in patients with renal impairment. -Ototoxicity: Use with caution in patients with pre-existing hearing loss. -Monitor renal function and auditory health during treatment. -Avoid concurrent use with other nephrotoxic or ototoxic drugs unless necessary.

Side Effects

-Common: Nausea, vomiting, headache, diarrhea. -Serious: Nephrotoxicity, ototoxicity, Clostridioides difficile-associated diarrhea, hypersensitivity reactions.

Drug Interactions

-Increased nephrotoxic risk with co-administration of nephrotoxic drugs (e.g., vancomycin, NSAIDs, amphotericin B). -Potential for ototoxicity when combined with other ototoxic agents (e.g., loop diuretics). -Reduced therapeutic effects when used with certain antacids or agents that bind to aminoglycosides.